These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23144888)

  • 1. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
    Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
    PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
    Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
    Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
    Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
    Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
    Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
    Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
    Srivastava AK; Dinc G; Sharma RK; Yolcu ES; Zhao H; Shirwan H
    Cancer Res; 2014 Nov; 74(22):6441-51. PubMed ID: 25252915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.
    Sharma RK; Yolcu ES; Srivastava AK; Shirwan H
    PLoS One; 2013; 8(9):e73145. PubMed ID: 24066030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
    Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
    Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fowlpox-based survivin vaccination for malignant mesothelioma therapy.
    Bertino P; Panigada M; Soprana E; Bianchi V; Bertilaccio S; Sanvito F; Rose AH; Yang H; Gaudino G; Hoffmann PR; Siccardi A; Carbone M
    Int J Cancer; 2013 Aug; 133(3):612-23. PubMed ID: 23335100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
    Sharma RK; Yolcu ES; Shirwan H
    Expert Rev Vaccines; 2014 Mar; 13(3):387-98. PubMed ID: 24521311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine.
    Harrison JM; Bertram EM; Boyle DB; Coupar BE; Ranasinghe C; Ramshaw IA
    Vaccine; 2006 Nov; 24(47-48):6867-74. PubMed ID: 17050052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
    Elvang T; Christensen JP; Billeskov R; Thi Kim Thanh Hoang T; Holst P; Thomsen AR; Andersen P; Dietrich J
    PLoS One; 2009; 4(4):e5139. PubMed ID: 19357780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
    Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.
    Bertram EM; Dawicki W; Sedgmen B; Bramson JL; Lynch DH; Watts TH
    J Immunol; 2004 Jan; 172(2):981-8. PubMed ID: 14707071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
    Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
    Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
    Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.